Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Continued to advance the development of CLD-401 towards the clinic
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.comSummary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.